|
The next NIH Small Business Innovation Research (SBIR) and Small
Business Technology Transfer (STTR) Omnibus funding opportunity deadline is
only weeks away on April 5, 2017. The National Heart, Lung, and
Blood Institute (NHLBI) welcomes all investigator-initiated projects within our
mission through these funding opportunities:
Learn about the NHLBI Mission
Additional Funding Opportunities Expiring
- Exp. April 6, 2017: Phase II Awardees - Commercialization
Readiness Pilot (CRP) Program: Technical Assistance ( PAR-16-026,
Notice about NHLBI participation NOT-HL-15-283)
-
Exp. Jan. 8, 2018: New Technologies for Viral
Hepatitis (SBIR
PA-15-077
STTR PA-15-076)
View all NHLBI Targeted Funding Opportunities on our website.
Get Ready
Contact us at NHLBI_SBIR@mail.nih.gov
for advice and assistance.
Please note
that NIH has published changes to the NIH’s Grant Appendix Policy, effective January
25, 2017 (NOT-OD-16-129).
The updated appendix policy eliminates most items that investigators previously
included in the application appendix. Elimination of most Appendix
materials is intended to rectify inequities in the peer review process that can
arise from submission of inappropriate or excessive Appendix materials by some
applicants and consideration of Appendix materials in peer review by some, but
not all reviewers. Applications will be withdrawn and not reviewed if
they are submitted with inappropriate appendix materials. This policy is
relevant for all funding mechanisms, including SBIR and STTR applications.
For more information read the full Notice NOT-OD-17-035 and view the Frequently Asked Questions Document at FAQs.
Seek NHLBI guidance while writing your Bridge
and Small Market Applications
Apply for up to $3M to
support continued development of your Phase II SBIR or STTR-funded heart, lung,
blood, or sleep technology requiring approval or clearance by a Federal
regulatory agency. The National Heart, Lung, and Blood Institute (NHLBI) SBIR Phase IIB Bridge
and Small Market Awards programs aim to de-risk your technology and encourage partnerships
between small businesses and investors and strategic partners.
Letters of Intent due May 19, 2017.
Applications due June 19, 2017.
For more information, please read the full Notice:
As a current NHLBI small business awardee, you
may be eligible to apply for a competing revision to
your award. A planned FOA, known as the Regenerative Medicine Innovation
Project (RMIP), is expected to publish in April/May and will support revision
projects that propose solutions to widely recognized issues in the development
of safe and effective regenerative medicine therapies. Application receipt
dates are expected in May/June 2017, and awards are anticipated in FY 2017.
To
learn more about this opportunity, please read NOT-HL-17-497
R43/R44 (SBIR) or NOT-HL-17-499
R41/R42 (STTR).
The NIH encourages investigators to use interim research products, such as preprints, to speed the dissemination and enhance the rigor of their work. Notice NOT-OD-17-050 clarifies reporting instructions to allow investigators to cite their interim research products and claim them as products of NIH funding.
Interim Research Products are complete, public research products that are not final.
For more information read the
full Notice NOT-OD-17-050
Thursday, May 25
Friday, May 26
8:00AM - 5:00PM ET
REGISTER HERE
The American Institute for Medical and Biological
Engineering (AIMBE), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), and the National Center for Advancing Translational Sciences
(NCATS) will be hosting a series of workshops.
The overall goal of this series is to develop guidelines for
investigators developing new microphysiological platform tools for the
pre-clinical, and possibly clinical, drug development process on how to
validate and qualify these new technologies so that they become useful and
meaningful tools.
Workshop topics:
- Toxicological applications(Workshops 1-4)
- Efficacy evaluation (Workshop 5)
- An update on the current state of technology and how
these systems can be applied to rare disease applications as well as regulatory
considerations. (Workshop 6)
Location:
NIH Main Campus
Natcher Conference Center
Ruth Kirschstein Auditorium, Bldg 45
9000 Rockville Pike
Bethesda, MD 20892
For more information, please check out the event website HERE
04/11
– 04/12 - AdvaMed Innovation Summit –
Washington, DC
04/18 – 04/20 - National Council of Entrepreneurial Tech Transfer
– Washington, DC
04/19 – 04/21 – Translational Science 2017 –
Washington, DC
04/19 – 04/21 - World
Orphan Drug Congress USA 2017 – Washington, DC
04/26 – 04/28 – 2017 Angel Capital
Association Summit – San Francisco, CA
05/01 – 05/03 – World Medical Innovation
Forum – Boston, MA
05/01 – 05/03 – 10x Medical Device Conference – San
Diego, CA
05/10 - 05/13 – The American Society of Gene & Cell Therapy
– Washington, DC
05/14 – 05/17 – National
SBIR/STTR Conference – Washington, DC
05/19 – 05/24 – American Thoracic Society International
Conference – Washington, DC
|
